Soft Tissue Sarcoma
296
62
89
106
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
54 trials with published results (18%)
Research Maturity
106 completed trials (36% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
37 terminated out of 296 trials
74.1%
-12.4% vs benchmark
6%
18 trials in Phase 3/4
51%
54 of 106 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 106 completed trials
Clinical Trials (296)
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Circulating Tumor DNA in Soft Tissue Sarcoma
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
Toripalimab Combined With CAV/IE Regimen